Clinical Trials Detalhe
The Prolonged Use of Topiramate for Preventing Migraine Headaches
Visão Geral
Gender
ALL
Idade
from 18 Years to 80 Years
Fase
PHASE3
Tipo de Estudo
INTERVENTIONAL
Localização
Coimbra, Portugal
Lisbon, Portugal
Porto, Portugal
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT00216619Sumário
The purpose of this study is to evaluate the safety and effectiveness (beyond 6 months) of individualized doses (100 to 200 milligrams) of topiramate for the prevention of migraine headaches over a period of 26 weeks.
Condições
Migraine
Elegibilidade
Inclusion Criteria: * Established history of migraine for at least one year; * Migraine meets HIS (International Headache Society) criteria * An average of at least 4 monthly migraine days during the 3 months preceding trial entry * Capable of keeping trial records; Exclusion Criteria: * Patient used migraine prophylactic medication in the month prior to trial entry (flunarizine: 3 months prior to entry) * Patient had failed (lack of efficacy) more than two adequate previous regimens of migraine prophylactic medications * Patient had a history of severe drug allergy or hypersensitivity * Patient overused analgesics, opiates, ergots and/or triptans * Patient had been using topiramate regularly